ClinicalTrials.gg
RecruitingNCT06939322LOG-IUpdated Nov 19, 2026

LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)

An interventional study of Use of the Log-AFTER software in Pediatric Cancer, Cancer Survivor and Hemato-oncologic Patients, sponsored by University Hospital, Angers. Recruiting at 1 site in France. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality.

In France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and/or access to therapeutic education in a video format. Indeed, there is the possibility of creating an GP account allowing to receive notifications concerning the follow-up of his patient to be scheduled, to have access to his file summary and his personalized follow-up plan, various information and blank prescription models. LOG-I is a study of the impact of the LOG-AFTER software for the "patient/GP" couple on adherence to follow-up recommendations. LOG-I is interested in all former patients with at least 3 recommendations in their personalized follow-up plan, taking into account the specific population of patients cured of a brain tumor.

Read the detailed description

Recruitment as long-term follow-up consultations progress. After checking the selection criteria, the investigator informs the patient of the study or the parents of the minor child orally and in writing with delivery of the information letter and answers any questions. If the patient, or their parents for minor patients, agrees to participate, the informed consent form is signed in 2 copies by the different parties. The date of the information and the date of signature of the consent are documented in the patient's source file. Following the inclusion of the patient, randomization is carried out (WITH and WITHOUT use of the LOG-AFTER software).

During this visit, for patients randomized in the LOG-AFTER software, an account is created within 5 days following the consultation.

For all patients (randomized with or without access to LOG-AFTER) the following data are collected in LOG-AFTER:

  • Health data: type of first cancer, start and end dates of treatment
  • Patient data required for research: gender, month and year of birth, after-effects, psychosocial data (level of education, life as a couple and children if concerned, profession if concerned).

The module to help create the Personalized After-Cancer Plan (PPAC) can be used for everyone and the PPAC is recorded in LOG-AFTER.

The PAM-13 questionnary is completed by the patient.

Contact with the GP : Following the patient's inclusion and randomization in the "WITH access to LOG-after" group, his GP is informed by mail and telephone call. He receives his codes by email via the software.

Patient follow-up : It is organized according to the habits of the specialist and/or his general practitioner.

For patients randomized with access to LOG-AFTER, patients are advised to report the completion of the examinations (date and overall conclusion of the examination), which allows the software to function properly. The GP is also advised to report any consultations his patient has had with him and to update the date of the examinations if his patient has not done so.

Visit at 36 months (+/- 3 months) • For patients randomized to the "LOG-AFTER" group: The patient is contacted 3 years after inclusion by the clinical research associate or reviewed in consultation by the doctor. The follow-up data according to the PPAC are updated if necessary in LOG-AFTER. If necessary, the PPAC can be updated and modified.

The satisfaction questionnaries (Software and Care Pathway) are given (paper format or via the software) to patients and GP. The PAM-13 questionnary is completed again by the patient. A telephone call (doctor or research associate) is made 2 weeks later if not completed with a proposal to do it by telephone.

  • For patients randomized to the "usual care" group: The patient is contacted 3 years after inclusion by the clinical research associate or reviewed in consultation by the doctor. The follow-up data according to the PPAC are collected in LOG-AFTER. A satisfaction questionnary on the care pathway (paper format or via software) is sent to patients and GP. The PAM-13 questionnaire is completed again by the patient. A telephone call (doctor or research associate) is made 2 weeks later if not completed with a proposal to do it by telephone.

At the end, an account is created for the patient/GP couple if the patient wishes.

02

Conditions studied

  • Pediatric Cancer
  • Cancer Survivor
  • Hemato-oncologic Patients

Browse trials for

Keywords

  • pediatry
  • oncology
  • hematology
  • radiotherapy
  • survivorship
  • preventive care
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 320 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University Hospital, Angers is the lead sponsor of 481 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated for cancer or malignant hematological pathology before the age of 25
  • Without residual disease or with a stable disease without treatment for 5 years or more
  • Owning a computer, smartphone or equivalent I-Pad/tablet with internet access
  • Having signed the consent (or their parents if the patient is a minor, or a third party if necessary)
  • Having 3 or more recommended screenings in their survivorship care plan
  • No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion

Exclusion criteria

Exclusion Criteria:

  • Patient who has or developed a second cancer with a post-treatment delay \< 5 years
  • Patient not covered by a health insurance
  • Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Use of the software Log-AFTER

    Patients are monitored with the help of LOG-AFTER software. Patients are advised to report the completion of the examinations (date and overall conclusion), which allows the software to function properly. The GP is also advised to report any consultations his patient has had with him and to update the date of the examinations if his patient has not done so.

    Other: Use of the Log-AFTER software

  • No intervention
    WITHOUT Log-After

    Patients are monitored without the LOG-AFTER software.

Interventions

  • OtherUse of the Log-AFTER software

    The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients

06

What researchers measure

Primary outcomes

  1. PPAC adherence

    Evaluate the impact of LOG-AFTER on former patients' adherence to the Personalized After-Cancer Plan (PPAC) for those with at least 3 follow-up examinations. (Adherence = For a number of screens between three and six (3-6), adherence is considered adequate if all screens or all but one screen have been completed. For seven or more screens (\>7), it is considered adequate if all screens or all but two screens have been completed)

    Time frame: 3 years

Secondary outcomes

  1. PPAC adherence for survivors of brain tumor treated, at least, with radiotherapy

    Evaluate the impact of LOG-AFTER on the adherence of former brain tumor patients who received radiotherapy to the Personalized After-Cancer Plan (PPAC) for those with at least 3 follow-up examinations. (Adherence = For a number of screens between three and six (3-6), adherence is considered adequate if all screens or all but one screen have been completed. For seven or more screens (\>7), it is considered adequate if all screens or all but two screens have been completed)

    Time frame: 3 years

  2. Health status

    Establish a descriptive overview of the health status of former patients based on the treatment received =\>Descriptive analysis of complications classified by Common Terminology Criteria for Adverse Events (CTCAE) score, including fatigue and cognitive impairment. The CTCAE is divided into 5 grades (from grade 1 = Mild; asymptomatic or mild symptoms; diagnosed by clinical examination only; not requiring treatment; to grade 5 = Death related to the adverse event.

    Time frame: 3 years

  3. PPAC adherence for new cancer survivors partients starting long term follow-up

    Describe the impact of LOG-AFTER on the adherence of new cancer survivors starting long term follow-up (Adherence = For a number of screens between three and six (3-6), adherence is considered adequate if all screens or all but one screen have been completed. For seven or more screens (\>7), it is considered adequate if all screens or all but two screens have been completed)

    Time frame: 3 years

  4. PPAC adherence for cancer survivors already involved in long term follow-up before the study

    Describe the impact of LOG-AFTER on the adherence of cancer survivors who are not new in long term follow-up (Adherence = For a number of screens between three and six (3-6), adherence is considered adequate if all screens or all but one screen have been completed. For seven or more screens (\>7), it is considered adequate if all screens or all but two screens have been completed)

    Time frame: 3 years

  5. Describe the patient satisfaction

    1. satisfaction score from the questionnaire derived from u-MARS for patients randomised with LOG-AFTER. 2. overall subjective score between 1 and 5 for patients randomised with LOG-AFTER. 3. qualitative aspect - open field questions, comments 4. qualitative aspect concerning the care pathway

    Time frame: 3 years

  6. GP satisfaction

    Satisfaction via questionnary derived from of the MARS (Mobile Application Rating Scale) (professionals) for those with access to LOG-AFTER. Overall subjective score between 1 (not satified) and 5 (completely satisfied) for those with access to LOG-AFTER. Qualitative aspect (free field)

    Time frame: 3 years

  7. Describe the use

    1. number of connections per user 2. number of connections per of account closures 3. number of inactive accounts (no use during 6 months or more)

    Time frame: 3 years

  8. Empowerment

    Patient Activation Measure® (PAM®)-13. The score can be 0 (patient not activated) to 100 (patient activated)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Angers
    Angers, Maine Et Loire 49933, France
    Recruiting
    • Charlotte DEMOOR-GOLDSCHMIDT, Dr · ContactCharlotte.DemoorGoldschmidt@chu-angers.fr · (+33)2 41 35 38 63
    • Pascal VEILLON, project manager · Contactpaveillon@chu-angers.fr · (+33)2 41 35 49 59
    • Charlotte DEMOOR-GOLDSCHMIDT, Dr · Principal investigator
    • Natacha ENTZ-WERLE, Pr · Principal investigator
    • Amandine BERTRAND, Dr · Principal investigator
    • Eric THEBAULT, Dr · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 29 months is close to that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Nov 2026 → Dec 2027 and completion Jun 2030 → Mar 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Apr 22, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Dec 5, 2027was Nov 2026
CompletionEst.
Mar 5, 2031was Jun 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 6, 2026→Dec 5, 2027
Nov 19, 2026
Study completion
Jun 6, 2030→Mar 5, 2031
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Nov 6, 2026→Dec 5, 2027
    Study completion Jun 6, 2030→Mar 5, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06939322
Collaborators
National Cancer Institute, France
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Jun 6, 2025
Primary completion
Dec 5, 2027 (estimated)
Completion
Mar 5, 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Sandra MERZEAU
Contact
samerzeau@chu-angers.fr
(+33)2 41 35 59 70 ext. +33
Pascal VEILLON
Contact
paveillon@chu-angers.fr
(+33)2 41 35 49 59 ext. +33
Charlotte DEMOOR-GOLDSCHMIDT, Dr
principal investigator · University Hospital of Angers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion